Authors: Nestorov, I Graham, G Duffull, S Aarons, L Fuseau, E Coates, P

Citation: I. Nestorov et al., Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan, PHARM RES, 18(8), 2001, pp. 1210-1219

Authors: Fuseau, E Petricoul, O Sabin, A Pereira, A O'Quinn, S Thein, S Leibowitz, M Purdon, H McNeal, S Salonen, R Metz, A

Citation: E. Fuseau et al., Effect of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine, CLIN THER, 23(2), 2001, pp. 242-251

Authors: Christensen, ML Eades, SK Fuseau, E Kempsford, RD Phelps, SJ Hak, LJ

Citation: Ml. Christensen et al., Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine, J CLIN PHAR, 41(2), 2001, pp. 170-175

Authors: Cox, EH Veyrat-Follet, C Beal, SL Fuseau, E Kenkare, S Sheiner, LB

Citation: Eh. Cox et al., A population pharmacokinetic-pharmacodynamic analysis of repeated measurestime-to-event pharmacodynamic responses: The antiemetic effect of ondansetron, J PHAR BIOP, 27(6), 1999, pp. 625-644

Authors: Cosson, VF Fuseau, E

Citation: Vf. Cosson et E. Fuseau, Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients, J PHAR BIOP, 27(2), 1999, pp. 149-171